secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001326110-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio reports preliminary FY2025 ANKTIVA revenue ~$113M, up ~700% YoY, and Saudi approval for NSCLC
--------------------------------------------------------------------------------

- Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.
- ANKTIVA unit sales volume grew 750% in 2025 vs 2024; quarter-over-quarter unit growth 54% during FY2025.
- Saudi FDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC (first global approval for this indication) and + BCG for NMIBC CIS.
- Phase 2b QUILT-2.005 trial enrollment ahead of expectations; full enrollment anticipated in H1 2026.
- Estimated cash, cash equivalents and marketable securities of $242.8M as of Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/0001326110-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20260115.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer